NCT03951220 2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
Clinical Trials
14 trialsNCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT02761187 2025-02-24
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
Terminated
NCT05986682 2025-02-03
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Duke University
Completed
NCT05061095 2024-12-27
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
Completed
NCT05932290 2024-10-29
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT05882279 2024-06-14
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
Takeda
Completed
NCT05565391 2024-05-21
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT02767388 2023-09-29
Chemobrain
University of Nebraska
Completed
NCT04172467 2022-01-10
QS-SID
AIO-Studien-gGmbH
Completed
NCT03506386 2021-02-08
MMyBRave
Takeda
Completed
NCT01804140 2016-11-02
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Genentech, Inc.
Completed
NCT00897910 2016-01-11
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Terminated
NCT01459653 2016-01-11
Monitor-GCSF
Sandoz
Completed